Browse
Want to filter the browse page content? No problem! Just select the filters below and click on the "Apply Filter" button.



Don't know the name of the drug? No problem! Just upload the image of the drug and we will identify it for you.

Identify Medicine

Want to calculate the risk of a drug that is not in our database? No problem! You can add it manually and we will calculate the risk for you.

Identify Risk

CLOPIDOGREL

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
CLOPIDOGREL

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TENECTEPLASE

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
TENECTEPLASE

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASPIRIN

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
ASPIRIN

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RAMIPRIL

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
RAMIPRIL

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PRASUGREL

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
PRASUGREL

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ATORVASTATIN

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
ATORVASTATIN

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EPTIFIBATIDE

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
EPTIFIBATIDE

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ABCIXIMAB

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
ABCIXIMAB

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TICAGRELOR

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
TICAGRELOR

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ENOXAPARIN

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
ENOXAPARIN

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASPIRIN

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
ASPIRIN____________________________

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALSARTAN

Used For: MYOCARDIAL INFARCTION

Average Sex Distribution in Clinical Studies
VALSARTAN

Age-Standardized Prevalence of MYOCARDIAL INFARCTION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 1.035 %
Prevalence in males: 2.67 %
Prevalence in both sexes: 1.81 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FUROSEMIDE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
FUROSEMIDE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DIGOXIN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
DIGOXIN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METOPROLOL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
METOPROLOL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METOLAZONE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
METOLAZONE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CAPTOPRIL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
CAPTOPRIL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CARVEDILOL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
CARVEDILOL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RAMIPRIL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
RAMIPRIL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALSARTAN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
VALSARTAN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SPIRONOLACTONE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
SPIRONOLACTONE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



HYDRALAZINE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
HYDRALAZINE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EPLERENONE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
EPLERENONE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ATORVASTATIN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
ATORVASTATIN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



IVABRADINE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
IVABRADINE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DOBUTAMINE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
DOBUTAMINE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MILRINONE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
MILRINONE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DAPAGLIFLOZIN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
DAPAGLIFLOZIN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SILDENAFIL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
SILDENAFIL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LISINOPRIL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
LISINOPRIL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RIVAROXABAN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
RIVAROXABAN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALLOPURINOL

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
ALLOPURINOL

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METFORMIN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
METFORMIN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ISOSORBIDE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
ISOSORBIDE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ISOSORBIDE DINITRATE

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
ISOSORBIDE_DINITRATE

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



WARFARIN

Used For: HEART FAILURE

Average Sex Distribution in Clinical Studies
WARFARIN

Age-Standardized Prevalence of HEART FAILURE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.905 %
Prevalence in males: 4.003 %
Prevalence in both sexes: 3.413 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALSARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
VALSARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ATENOLOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ATENOLOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



AMLODIPINE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
AMLODIPINE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RAMIPRIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
RAMIPRIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



IRBESARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
IRBESARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FUROSEMIDE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
FUROSEMIDE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



AMLODIPINE BESYLATE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
AMLODIPINE_BESYLATE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TRANDOLAPRIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
TRANDOLAPRIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LOSARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
LOSARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FELODIPINE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
FELODIPINE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LISINOPRIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
LISINOPRIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



NITROGLYCERIN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
NITROGLYCERIN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LABETALOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
LABETALOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



NIFEDIPINE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
NIFEDIPINE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CANDESARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
CANDESARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



HYDRALAZINE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
HYDRALAZINE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CLONIDINE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
CLONIDINE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TELMISARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
TELMISARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ENALAPRIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ENALAPRIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



QUINAPRIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
QUINAPRIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INDAPAMIDE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
INDAPAMIDE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METOPROLOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
METOPROLOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PROPRANOLOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
PROPRANOLOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METOPROLOL TARTRATE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
METOPROLOL_TARTRATE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SILDENAFIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
SILDENAFIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PERINDOPRIL ERBUMINE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
PERINDOPRIL_ERBUMINE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METFORMIN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
METFORMIN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ATORVASTATIN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ATORVASTATIN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



HYDROCHLOROTHIAZIDE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
HYDROCHLOROTHIAZIDE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BISOPROLOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
BISOPROLOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OLMESARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
OLMESARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROSUVASTATIN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ROSUVASTATIN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CANDESARTAN CILEXETIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
CANDESARTAN_CILEXETIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASPIRIN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ASPIRIN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SPIRONOLACTONE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
SPIRONOLACTONE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PERINDOPRIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
PERINDOPRIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EZETIMIBE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
EZETIMIBE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALISKIREN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ALISKIREN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LOSARTAN POTASSIUM

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
LOSARTAN_POTASSIUM

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CARVEDILOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
CARVEDILOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EPROSARTAN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
EPROSARTAN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CHLORTHALIDONE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
CHLORTHALIDONE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OLMESARTAN MEDOXOMIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
OLMESARTAN_MEDOXOMIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DOXAZOSIN

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
DOXAZOSIN

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



NEBIVOLOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
NEBIVOLOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SODIUM

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
SODIUM

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DIURETIC

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
DIURETIC

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EPLERENONE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
EPLERENONE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PERINDOPRIL ARGININE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
PERINDOPRIL_ARGININE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TADALAFIL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
TADALAFIL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALLOPURINOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
ALLOPURINOL

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BISOPROLOL

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
BISOPROLOL_________________________

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



AMILORIDE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
AMILORIDE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



HYPROMELLOSE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
HYPROMELLOSE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SODIUM NITROPRUSSIDE

Used For: HYPERTENSION

Average Sex Distribution in Clinical Studies
SODIUM_NITROPRUSSIDE

Age-Standardized Prevalence of HYPERTENSION in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 22.485 %
Prevalence in males: 22.913 %
Prevalence in both sexes: 22.749 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASPIRIN

Used For: ISCHEMIC HEART DISEASE

Average Sex Distribution in Clinical Studies
ASPIRIN

Age-Standardized Prevalence of ISCHEMIC HEART DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.095 %
Prevalence in males: 9.731 %
Prevalence in both sexes: 7.815 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALSARTAN

Used For: ISCHEMIC HEART DISEASE

Average Sex Distribution in Clinical Studies
VALSARTAN

Age-Standardized Prevalence of ISCHEMIC HEART DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.095 %
Prevalence in males: 9.731 %
Prevalence in both sexes: 7.815 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASPIRIN

Used For: ISCHEMIC HEART DISEASE

Average Sex Distribution in Clinical Studies
ASPIRIN____________________________

Age-Standardized Prevalence of ISCHEMIC HEART DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.095 %
Prevalence in males: 9.731 %
Prevalence in both sexes: 7.815 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASPIRIN

Used For: STROKE

Average Sex Distribution in Clinical Studies
ASPIRIN

Age-Standardized Prevalence of STROKE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.305 %
Prevalence in males: 2.786 %
Prevalence in both sexes: 2.526 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CLOPIDOGREL

Used For: STROKE

Average Sex Distribution in Clinical Studies
CLOPIDOGREL

Age-Standardized Prevalence of STROKE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.305 %
Prevalence in males: 2.786 %
Prevalence in both sexes: 2.526 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALTEPLASE

Used For: STROKE

Average Sex Distribution in Clinical Studies
ALTEPLASE

Age-Standardized Prevalence of STROKE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.305 %
Prevalence in males: 2.786 %
Prevalence in both sexes: 2.526 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RIVAROXABAN

Used For: STROKE

Average Sex Distribution in Clinical Studies
RIVAROXABAN

Age-Standardized Prevalence of STROKE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.305 %
Prevalence in males: 2.786 %
Prevalence in both sexes: 2.526 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



APIXABAN

Used For: STROKE

Average Sex Distribution in Clinical Studies
APIXABAN

Age-Standardized Prevalence of STROKE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 2.305 %
Prevalence in males: 2.786 %
Prevalence in both sexes: 2.526 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TIOTROPIUM

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
TIOTROPIUM

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ADVAIR

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
ADVAIR

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



THEOPHYLLINE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
THEOPHYLLINE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREDNISONE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
PREDNISONE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



IPRATROPIUM

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
IPRATROPIUM

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALBUTEROL

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
ALBUTEROL

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MOXIFLOXACIN

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
MOXIFLOXACIN

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BUDESONIDE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
BUDESONIDE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE PROPIONATE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
FLUTICASONE_PROPIONATE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROFLUMILAST

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
ROFLUMILAST

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OXYGEN

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
OXYGEN

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLYCOPYRRONIUM

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
GLYCOPYRRONIUM

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
FLUTICASONE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ACLIDINIUM BROMIDE FORMOTEROL FUMARATE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
ACLIDINIUM_BROMIDE_FORMOTEROL_FUMARATE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DOXYCYCLINE

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
DOXYCYCLINE

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE SALMETEROL

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
FLUTICASONE_SALMETEROL

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BENRALIZUMAB

Used For: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Average Sex Distribution in Clinical Studies
BENRALIZUMAB

Age-Standardized Prevalence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 8.456 %
Prevalence in males: 9.465 %
Prevalence in both sexes: 8.876 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLYBURIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
GLYBURIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INSULIN GLARGINE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
INSULIN_GLARGINE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METFORMIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
METFORMIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROSIGLITAZONE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ROSIGLITAZONE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SITAGLIPTIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
SITAGLIPTIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INSULIN LISPRO

Used For: DIABETES

Average Sex Distribution in Clinical Studies
INSULIN_LISPRO

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INSULIN DETEMIR

Used For: DIABETES

Average Sex Distribution in Clinical Studies
INSULIN_DETEMIR

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PIOGLITAZONE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
PIOGLITAZONE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RAMIPRIL

Used For: DIABETES

Average Sex Distribution in Clinical Studies
RAMIPRIL

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLICLAZIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
GLICLAZIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INSULIN ISOPHANE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
INSULIN_ISOPHANE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LISINOPRIL

Used For: DIABETES

Average Sex Distribution in Clinical Studies
LISINOPRIL

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EZETIMIBE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
EZETIMIBE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLIMEPIRIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
GLIMEPIRIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ACARBOSE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ACARBOSE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROSUVASTATIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ROSUVASTATIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INSULIN DEGLUDEC

Used For: DIABETES

Average Sex Distribution in Clinical Studies
INSULIN_DEGLUDEC

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



REPAGLINIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
REPAGLINIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ATORVASTATIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ATORVASTATIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ISLET CELL TRANSPLANT

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ISLET_CELL_TRANSPLANT

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALSARTAN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
VALSARTAN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SAXAGLIPTIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
SAXAGLIPTIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LIRAGLUTIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
LIRAGLUTIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DAPAGLIFLOZIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
DAPAGLIFLOZIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



IRBESARTAN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
IRBESARTAN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CANDESARTAN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
CANDESARTAN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LINAGLIPTIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
LINAGLIPTIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREGABALIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
PREGABALIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CANAGLIFLOZIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
CANAGLIFLOZIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREDNISONE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
PREDNISONE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALOGLIPTIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ALOGLIPTIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SEMAGLUTIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
SEMAGLUTIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FENOFIBRATE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
FENOFIBRATE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DULAGLUTIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
DULAGLUTIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PANTOPRAZOLE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
PANTOPRAZOLE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DEXAMETHASONE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
DEXAMETHASONE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLIPIZIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
GLIPIZIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



EXENATIDE

Used For: DIABETES

Average Sex Distribution in Clinical Studies
EXENATIDE

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ABATACEPT

Used For: DIABETES

Average Sex Distribution in Clinical Studies
ABATACEPT

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BASAL INSULIN

Used For: DIABETES

Average Sex Distribution in Clinical Studies
BASAL_INSULIN

Age-Standardized Prevalence of DIABETES in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.334 %
Prevalence in males: 7.896 %
Prevalence in both sexes: 7.08 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BUDESONIDE FORMOTEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
BUDESONIDE___FORMOTEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MONTELUKAST

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
MONTELUKAST

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



AZITHROMYCIN

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
AZITHROMYCIN

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OMALIZUMAB

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
OMALIZUMAB

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALBUTEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
ALBUTEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ADVAIR

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
ADVAIR

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CICLESONIDE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
CICLESONIDE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



IPRATROPIUM

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
IPRATROPIUM

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE PROPIONATE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE_PROPIONATE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TIOTROPIUM

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
TIOTROPIUM

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREDNISONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
PREDNISONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ADVAIR DISKUS

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
ADVAIR_DISKUS

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SALMETEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
SALMETEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE FUROATE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE_FUROATE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BECLOMETHASONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
BECLOMETHASONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLOVENT DISKUS

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLOVENT_DISKUS

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BUDESONIDE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
BUDESONIDE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREDNISOLONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
PREDNISOLONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METHYLPREDNISOLONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
METHYLPREDNISOLONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FORMOTEROL FUMARATE DIHYDRATE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FORMOTEROL_FUMARATE_DIHYDRATE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALBUTEROL SULFATE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
ALBUTEROL_SULFATE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MOMETASONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
MOMETASONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TERBUTALINE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
TERBUTALINE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CETIRIZINE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
CETIRIZINE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



THEOPHYLLINE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
THEOPHYLLINE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DEXAMETHASONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
DEXAMETHASONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MEPOLIZUMAB

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
MEPOLIZUMAB

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BUDESONIDE FORMOTEROL FUMARATE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
BUDESONIDE_FORMOTEROL_FUMARATE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLYCOPYRRONIUM

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
GLYCOPYRRONIUM

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE PROPIONATE SALMETEROL XINAFOATE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE_PROPIONATE_SALMETEROL_XINAFOATE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE PROPIONATE SALMETEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE_PROPIONATE_SALMETEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LEVALBUTEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
LEVALBUTEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BENRALIZUMAB

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
BENRALIZUMAB

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DUPILUMAB

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
DUPILUMAB

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OXYGEN

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
OXYGEN

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE SALMETEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE_SALMETEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



QVM149

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
QVM149

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RESLIZUMAB

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
RESLIZUMAB

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUTICASONE PROPIONATE AND SALMETEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
FLUTICASONE_PROPIONATE_AND_SALMETEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROFLUMILAST

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
ROFLUMILAST

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OLODATEROL

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
OLODATEROL

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BUDESONIDE FORMOTER

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
BUDESONIDE_FORMOTER

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ESCITALOPRAM

Used For: ASTHMA

Average Sex Distribution in Clinical Studies
ESCITALOPRAM

Age-Standardized Prevalence of ASTHMA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 10.686 %
Prevalence in males: 9.551 %
Prevalence in both sexes: 10.146 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RIVASTIGMINE

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
RIVASTIGMINE

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DONEPEZIL

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
DONEPEZIL

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MEMANTINE

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
MEMANTINE

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GALANTAMINE

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
GALANTAMINE

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ARIPIPRAZOLE

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
ARIPIPRAZOLE

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CITALOPRAM

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
CITALOPRAM

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DONEPEZIL HYDROCHLORIDE

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
DONEPEZIL_HYDROCHLORIDE

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BREXPIPRAZOLE

Used For: DEMENTIA

Average Sex Distribution in Clinical Studies
BREXPIPRAZOLE

Age-Standardized Prevalence of DEMENTIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 6.683 %
Prevalence in males: 5.729 %
Prevalence in both sexes: 6.332 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RISPERIDONE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
RISPERIDONE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CLOZAPINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
CLOZAPINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OLANZAPINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
OLANZAPINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



QUETIAPINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
QUETIAPINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SERTRALINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
SERTRALINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ARIPIPRAZOLE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
ARIPIPRAZOLE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



HALOPERIDOL

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
HALOPERIDOL

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PALIPERIDONE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
PALIPERIDONE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LOXAPINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
LOXAPINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PIMOZIDE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
PIMOZIDE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LAMOTRIGINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
LAMOTRIGINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ASENAPINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
ASENAPINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUOXETINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
FLUOXETINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CHLORPROMAZINE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
CHLORPROMAZINE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LURASIDONE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
LURASIDONE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LORAZEPAM

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
LORAZEPAM

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ZIPRASIDONE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
ZIPRASIDONE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CITALOPRAM

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
CITALOPRAM

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BREXPIPRAZOLE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
BREXPIPRAZOLE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BUPROPION

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
BUPROPION

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALPROATE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
VALPROATE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



QUETIAPINE FUMARATE

Used For: SCHIZOPHRENIA

Average Sex Distribution in Clinical Studies
QUETIAPINE_FUMARATE

Age-Standardized Prevalence of SCHIZOPHRENIA in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.664 %
Prevalence in males: 0.932 %
Prevalence in both sexes: 0.8 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CARBAMAZEPINE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
CARBAMAZEPINE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GABAPENTIN

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
GABAPENTIN

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TOPIRAMATE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
TOPIRAMATE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PHENYTOIN

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
PHENYTOIN

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OXCARBAZEPINE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
OXCARBAZEPINE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CLOBAZAM

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
CLOBAZAM

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LAMOTRIGINE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
LAMOTRIGINE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALPROIC ACID

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
VALPROIC_ACID

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DIVALPROEX SODIUM

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
DIVALPROEX_SODIUM

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VALPROATE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
VALPROATE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LEVETIRACETAM

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
LEVETIRACETAM

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LACOSAMIDE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
LACOSAMIDE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PERAMPANEL

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
PERAMPANEL

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREGABALIN

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
PREGABALIN

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LORAZEPAM

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
LORAZEPAM

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



MEMANTINE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
MEMANTINE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BRIVARACETAM

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
BRIVARACETAM

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SODIUM

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
SODIUM

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FLUOXETINE

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
FLUOXETINE

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VITAMIN

Used For: EPILEPSY

Average Sex Distribution in Clinical Studies
VITAMIN

Age-Standardized Prevalence of EPILEPSY in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.775 %
Prevalence in males: 0.844 %
Prevalence in both sexes: 0.806 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INTERFERON BETA-1A

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
INTERFERON_BETA-1A

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLATIRAMER

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
GLATIRAMER

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INTERFERON BETA-1B

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
INTERFERON_BETA-1B

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



NATALIZUMAB

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
NATALIZUMAB

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



METHYLPREDNISOLONE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
METHYLPREDNISOLONE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ARBACLOFEN

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
ARBACLOFEN

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



VITAMIN D3

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
VITAMIN_D3

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PREDNISONE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
PREDNISONE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



FINGOLIMOD

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
FINGOLIMOD

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



BACLOFEN

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
BACLOFEN

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RITUXIMAB

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
RITUXIMAB

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DALFAMPRIDINE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
DALFAMPRIDINE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



DIMETHYL FUMARATE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
DIMETHYL_FUMARATE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TERIFLUNOMIDE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
TERIFLUNOMIDE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OCRELIZUMAB

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
OCRELIZUMAB

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ALEMTUZUMAB

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
ALEMTUZUMAB

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CLADRIBINE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
CLADRIBINE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SIPONIMOD

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
SIPONIMOD

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OFATUMUMAB

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
OFATUMUMAB

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



GLATIRAMER ACETATE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
GLATIRAMER_ACETATE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CHOLECALCIFEROL

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
CHOLECALCIFEROL

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CYCLOPHOSPHAMIDE

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
CYCLOPHOSPHAMIDE

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



INTERFERON-BETA

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
INTERFERON-BETA

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CITALOPRAM

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
CITALOPRAM

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



OZANIMOD

Used For: MULTIPLE SCLEROSIS

Average Sex Distribution in Clinical Studies
OZANIMOD

Age-Standardized Prevalence of MULTIPLE SCLEROSIS in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.359 %
Prevalence in males: 0.139 %
Prevalence in both sexes: 0.251 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



PRAMIPEXOLE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
PRAMIPEXOLE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ENTACAPONE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
ENTACAPONE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RIVASTIGMINE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
RIVASTIGMINE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



AMANTADINE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
AMANTADINE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



RASAGILINE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
RASAGILINE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



LEVODOPA

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
LEVODOPA

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROPINIROLE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
ROPINIROLE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



TOPIRAMATE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
TOPIRAMATE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



ROTIGOTINE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
ROTIGOTINE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



APOMORPHINE

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
APOMORPHINE

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



CARBIDOPA

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
CARBIDOPA

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



SODIUM

Used For: PARKINSON'S

Average Sex Distribution in Clinical Studies
SODIUM

Age-Standardized Prevalence of PARKINSON'S in Canadians Aged 1 Years and Older (2021-2022) *
Prevalence in females: 0.337 %
Prevalence in males: 0.521 %
Prevalence in both sexes: 0.418 %

*retrieved from https://health-infobase.canada.ca/ccdss/data-tool/
Save



Disclaimer

​​unbIAsed.Rx is not affiliated with any pharmaceutical companies and does not endorse drugs, diagnose patients, or recommend therapy. This resource is designed to assist licensed healthcare practitioners in caring for their patients, provide consumers with drug-specific information, and raise awareness of sex disparities in pharmaceuticals and the underrepresentation of women and gender-diverse individuals in clinical trials. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect as the drug information contained herein may be time sensitive.

Always consult with a healthcare professional before making any medical decisions or changes to your treatment plan. The information on this site is not a substitute for professional medical advice and healthcare practitioners should use their professional judgment in using the information provided.

By using this product, you acknowledge and accept these disclaimers and limitations.